Please ensure Javascript is enabled for purposes of website accessibility Amnealbiosciences

The future of accessible medicines

About Biosimilars

What is a Biosimilar?

A biosimilar is a biologic medicine that is highly similar to the reference product notwithstanding minor differences in clinically inactive components. According to the US Food and Drug Administration (FDA), biosimilarity means there are no clinically meaningful differences between the biological product and the FDA-approved reference product in terms of the safety, purity, and potency.

This is biosimilar image
This is image

How are Biosimilar diffrent from other generic medicine

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business as well as deepening portfolios in.

How are Biosimilars different from other generic medicines?

This is image

Antibiotic

Small Chemical Molecule

This is image
This is image

Calcitonin

Simple biologic

This is image
This is image

Filgrastim

Minor complex biologic

This is image
This is image

Erythropoietin

Moderate complex biologic

This is image
This is image

mAb

Complex biologic

This is image

Biologics are far more structurally complex than small molecule pharmaceuticals such as antibiotics.

The value of biosimilars

This is image

Biosimilars are projected to save an estimated $38.4 billion from 2021 to 20251

This is image

Biosimilars are approved according to the US FDA’s rigorous standards

This is image

Lower costs also mean greater accessibility for patients who need it most

This is image

Their safety is continually monitored through post-marketing surveillance

  1. Projected US Savings From Biosimilars, 2021–2025. Published in: American Journal of Managed Care, Volume 28, No. 7 (July 2022) Posted on RAND.org on January 26, 2022 (https://www.rand.org/pubs/external_publications/EP68829.html)

Messaging Headline Goes here. lorem ipsum dolor

This is image

Headline reflacting benifits

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old.

This is image

Headline reflacting benifits

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old.

This is image

Headline reflacting benifits

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old.

This is image

Headline reflacting benifits

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old.

This is image

Headline reflacting benifits

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old.

This is image

Headline reflacting benifits

Contrary to popular belief, Lorem Ipsum is not simply random text. It has roots in a piece of classical Latin literature from 45 BC, making it over 2000 years old.

Approval Pathway2

Biosimilar medicines undergo a rigorous regulatory approval process to ensure efficacy, safety and quality. Since safety and efficacy have already been established for the reference biologic, the goal of the biosimilar development program is not to require additional large clinical studies, but rather to demonstrate that the compound is highly similar to the reference product with no clinically meaningful differences. It does this using a stepwise approach outlined in the Biologics Price Competition and Innovation Act (BPCI Act). A biosimilar product application must include data demonstrating biosimilarity to the reference product. This usually includes data from:

Learn more about the US FDA approval process at FDA.gov.

This site is intended only for U.S. residents. The information contained herein is provided for educational purposes only and is not intended to replace discussions with a licensed healthcare provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

Something went wrong: cURL error 28: Resolving timed out after 10519 milliseconds